Home Cart Sign in  
Chemical Structure| 1956370-21-0 Chemical Structure| 1956370-21-0

Structure of RIPA-56
CAS No.: 1956370-21-0

Chemical Structure| 1956370-21-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RIPA-56 is a RIP1 inhibitor with EC50 value of 28nM. It efficiently reduced TNFα-induced mortality and multi-organ damage.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RIPA-56

CAS No. :1956370-21-0
Formula : C13H19NO2
M.W : 221.30
SMILES Code : CCC(C)(C)C(N(CC1=CC=CC=C1)O)=O
MDL No. :MFCD30738006
InChI Key :AVYVHIKSFXVDBG-UHFFFAOYSA-N
Pubchem ID :121439991

Safety of RIPA-56

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H315-H319
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of RIPA-56

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human renal tubular epithelial cells (HK-2) 100 nM 24 hours To evaluate the inhibitory effect of RIPA-56 on necroptosis in HK-2 cells stimulated by high glucose and palmitic acid. Results showed that RIPA-56 significantly suppressed the expression of p-RIPK1/p-RIPK3/p-MLKL and reduced p-MLKL membrane translocation. PMC10624943
R28 cells 2 μM, 4 μM, 8 μM 24 hours To evaluate the protective effect of RIPA-56 on glutamate-induced damage in R28 cells. Results showed that RIPA-56 significantly increased cell viability, reduced apoptosis and mitochondrial membrane potential changes, and decreased ROS levels. PMC10869350

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice (C57BLKS-Leprdb) High-fat diet-induced diabetic kidney disease model Oral 300 mg/kg 36 consecutive days To evaluate the protective effects of RIPA-56 in a high-fat diet-induced diabetic kidney disease mouse model. Results showed that RIPA-56 significantly improved renal function (BUN and ACR), alleviated glomerular and tubulointerstitial pathological damage, and inhibited necroptosis pathway activation (p-RIPK1/p-RIPK3/p-MLKL). PMC10624943
C57BL/6j mice NMDA-induced normal tension glaucoma mice model Intravitreal injection 60 μM, 80 μM, 100 μM Single injection, observed for 3 days To evaluate the protective effect of RIPA-56 on NMDA-induced retinal damage. Results showed that RIPA-56 significantly reduced retinal ganglion cell loss, improved retinal structure, and decreased the expression of the inflammatory marker IL-6. PMC10869350
Mice Carbon tetrachloride/Galactosamine-induced ACLF model Intraperitoneal injection 3 mg/kg Twice daily for 48 hours To evaluate the protective effect of RIPA56 on hepatocyte necroptosis in the ACLF model. Results showed that RIPA56 significantly reduced liver injury (decreased ALT levels), hepatocyte death (reduced TUNEL staining), and liver RIPK3 and pMLK expression. PMC8683430

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.52mL

0.90mL

0.45mL

22.59mL

4.52mL

2.26mL

45.19mL

9.04mL

4.52mL

References

 

Historical Records

Categories